/
MBIO
$0.70-$0.00 (-0.53%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$5.3M
8M shares
52-week range
$0.53 – $7.00
3% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.84%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-2519.30
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $630.0K | $1.4M | $1.8M | $2.3M | $3.0M | $2.2M | $0 | $41.0K |
| Gross profit | −$630.0K | −$1.4M | −$1.8M | −$2.3M | −$3.0M | −$2.2M | $0 | −$41.0K |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $24.5M | $36.3M | $45.6M | $53.5M | $63.9M | $39.2M | $8.4M | $1.5M |
| Operating income | −$31.2M | −$45.9M | −$56.8M | −$66.7M | −$76.2M | −$50.7M | −$16.2M | −$2.4M |
| EBITDA | −$30.0M | −$43.3M | −$54.3M | −$64.0M | −$71.1M | −$48.1M | −$14.9M | −$1.9M |
| Net income | −$30.7M | −$48.2M | −$60.0M | −$66.4M | −$77.5M | −$51.6M | −$15.8M | −$1.9M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -17.07 | -20.03 | -17.10 | -11.40 | -11.25 | -6.00 | -2.57 | -0.39 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $11M | $-99.00 | $-99.00–$-99.00 | 1 |
| 2027 | $56M | $-51.50 | $-51.50–$-51.50 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$2.93
Price
$0.70
Implied upside
+319%
Peer comparison
Mustang Bio, Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
www.mustangbio.com- Employees
- 4
- IPO / List date
- Aug 22, 2017
- HQ
- WALTHAM, MA
Held by traders on TradeandTell
No one on the platform currently holds MBIO.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-09-30 | 11,800 | $17.9K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2025-01-16 | 1-for-50reverse |
| 2023-04-04 | 1-for-15reverse |
Recent trades on TradeandTell
No one on the platform has traded MBIO yet.
